Medical genetics of Jews
The medical genetics of Jews is the study, screening, and treatment of genetic disorders more common in genetically-associated Jewish populations than in the population as a whole. The genetics of Ashkenazi Jews have been particularly well-studied, resulting in the discovery of many genetic disorders associated with this ethnic group.
In contrast, the medical genetics of Sephardic Jews and Mizrahi Jews are more complicated, since they are more genetically diverse and consequently no genetic disorders are more common in these groups as a whole; instead, they tend to have the genetic diseases common in their various countries of origin.
Several organizations, such as Dor Yeshorim, offer screening for Ashkenazi genetic diseases, and these screening programs have had a significant impact, in particular by reducing the number of cases of Tay–Sachs disease.
Genetics of Jewish populations
Different ethnic groups tend to suffer from different rates of hereditary diseases, with some being more common, and some less common. Hereditary diseases, particularly hemophilia, were recognized early in Jewish history, even being described in the Talmud. However, the scientific study of hereditary disease in Jewish populations was initially hindered by scientific racism, which was based on racial supremacism.
However, modern studies on the genetics of particular ethnic groups have the tightly defined purpose of avoiding the birth of children with genetic diseases, or identifying people at particular risk of developing a disease in the future. Consequently, some members of the Jewish community[who?] has been very supportive of modern genetic testing programs; this high level of cooperation has raised concerns that conclusions may lead to stigmatization of the Jewish community.
However, most populations contain hundreds of alleles that could potentially cause disease and most people are heterozygotes for one or two recessive alleles that would be lethal in a homozygote. Although the overall frequency of disease-causing alleles does not vary much between populations, the practice of consanguineous marriage (marriage between second cousins or closer relatives) is common in some Jewish communities, which produces a small increase in the number of children with congenital defects.
- Jewish populations, and particularly the large Ashkenazi Jewish population, are ideal for such research studies, because they exhibit a high degree of endogamy, and at the same time are a large group.
- Jewish populations are overwhelmingly urban and are concentrated near biomedical centers where such research has been carried out.
The result is a form of ascertainment bias. This has sometimes created an impression that Jews are more susceptible to genetic disease than other populations. Carmeli writes, "Jews are over-represented in human genetic literature, particularly in mutation-related contexts."
This set of advantages have led to Ashkenazi Jews in particular being used in many genetic studies, not just in the study of genetic diseases. For example, a series of publications on Ashkenazi centenarians established their longevity was strongly inherited and associated with lower rates of age-related diseases. This "healthy aging" phenotype may be due to higher levels of telomerase in these individuals. It may also be due to the well established correlation between high intelligence and longevity. 
Today's 10 million Ashkenazi Jews descend from a population of only 350 individuals who lived about 600–800 years ago. That population derived from both Europe and the Middle East. There is evidence that the population bottleneck may have allowed deleterious alleles to become more prevalent in the population due to genetic drift. As a result, this group has been particularly intensively studied, so many mutations have been identified as common in Ashkenazim. Of these diseases, many also occur in other Jewish groups and in non-Jewish populations, although the specific mutation which causes the disease may vary between populations. For example, two different mutations in the glucocerebrosidase gene causes Gaucher's disease in Ashkenazim, which is their most common genetic disease, but only one of these mutations is found in non-Jewish groups. A few diseases are unique to this group; for example, familial dysautonomia is almost unknown in other populations.
|Disease||Mode of inheritance||Gene||Carrier frequency|
|Bloom syndrome||Autosomal recessive||BLM||1/100|
|Breast cancer and ovarian cancer||Autosomal dominant||BRCA1 or BRCA2||1/100 and 1/75, respectively|
|Canavan disease||Autosomal recessive||ASPA||1/60|
|Congenital deafness||Autosomal recessive||GJB2 or GJB6||1/25|
|Cystic fibrosis||Autosomal recessive||CFTR||1/25|
|Haemophilia C||Autosomal recessive||F11||1/12|
|Familial dysautonomia||Autosomal recessive||IKBKAP||1/30|
|Familial hypercholesterolemia||Autosomal dominant||LDLR||1/69|
|Familial hyperinsulinism||Autosomal recessive||ABCC8||1/125–1/160|
|Fanconi anemia C||Autosomal recessive||FACC||1/100|
|Gaucher disease||Autosomal recessive||GBA||1/7–1/18|
|Glycogen Storage Disease type 1a||Autosomal recessive||G6PC||1/71|
|Mucolipidosis IV||Autosomal recessive||MCOLN1||1/110|
|Niemann–Pick (type A)||Autosomal recessive||SMPD1||1/90|
|Nonclassical 21 OHase deficiency||Autosomal recessive||CPY21||1/6|
|Parkinson's disease||Autosomal dominant||LRRK2||1/42|
|Torsion dystonia||Autosomal dominant||DYT1||1/4000|
|Usher syndrome||Autosomal recessive||PCDH15||1/72|
Tay–Sachs disease, which can present as a fatal illness of children that causes mental deterioration prior to death, was historically extremely common among Ashkenazi Jews, with lower levels of the disease in some Pennsylvania Dutch, southern Louisiana Cajun, and eastern Quebec French Canadian populations. Since the 1970s, however, proactive genetic testing has been quite effective in eliminating Tay–Sachs from the Ashkenazi Jewish population.
Lipid transport diseases
Gaucher's disease, in which lipids accumulate in inappropriate locations, occurs most frequently among Ashkenazi Jews; the mutation is carried by roughly one in every 15 Ashkenazi Jews, compared to one in 100 of the general American population. Gaucher's disease can cause brain damage and seizures, but these effects are not usually present in the form manifested among Ashkenazi Jews; while sufferers still bruise easily, and it can still potentially rupture the spleen, it generally has only a minor impact on life expectancy.
Ashkenazi Jews are also highly affected by other lysosomal storage diseases, particularly in the form of lipid storage disorders. Compared to other ethnic groups, they more frequently act as carriers of mucolipidosis and Niemann–Pick disease, the latter of which can prove fatal.
The occurrence of several lysosomal storage disorders in the same population suggests the alleles responsible might have conferred some selective advantage in the past. This would be similar to the hemoglobin allele which is responsible for sickle-cell disease, but solely in people with two copies; those with just one copy of the allele have a sickle cell trait and gain partial immunity to malaria as a result. This effect is called heterozygote advantage.
Familial dysautonomia (Riley–Day syndrome), which causes vomiting, speech problems, an inability to cry, and false sensory perception, is almost exclusive to Ashkenazi Jews; Ashkenazi Jews are almost 100 times more likely to carry the disease than anyone else.
Other Ashkenazi diseases and disorders
Diseases inherited in an autosomal recessive pattern often occur in endogamous populations. Among Ashkenazi Jews, a higher incidence of specific genetic disorders and hereditary diseases have been verified, including:
- Colorectal cancer due to hereditary nonpolyposis colorectal cancer
- Congenital adrenal hyperplasia (nonclassical form) 
- Congenital insensitivity to pain with anhidrosis
- Crohn's disease (the NOD2/CARD15 locus appears to be implicated)
- Joubert syndrome type 2 is disproportionately frequent among people of Jewish descent; this has been attributed to the resistance to intermarriage of this population.
- Kaposi's sarcoma
- Maple syrup urine disease 
- Mucolipidosis IV 
- Myeloproliferative Neoplasms including Polycythemia Vera and Essential Thrombocythemia 
- Nonsyndromic hearing loss and deafness, DFNB1 (connexin 26) 
- Parkinson's disease (G2019S/LRRK2 mutation; The LRRK2 mutation on the main haplotype, shared by Ashkenazi Jews, North Africans, and Europeans, initially arose in the Near East at least 4000 years ago. Because of a founder effect, the ancestors of present-day Ashkenazi Jews may have kept the low-frequency G2019S mutation through the different diasporas, whereas Near Eastern daughter populations lost the mutation. The mutation might then have been "reintroduced by recurrent gene flow from Ashkenazi populations to other Jewish, European, and North African populations. The present-day frequency of the mutation in control populations (0.05% in Europeans, 0.5% in North-African Arabs and 1% in Ashkenazi Jews) may support this scenario".)
- Pemphigus vulgaris
- Schizophrenia (DNST3 gene variation)
- Von Gierke disease
- Zellweger syndrome
In contrast to the Ashkenazi population, Sephardic and Mizrahi Jews are much more divergent groups, with ancestors from Spain, Portugal, Morocco, Tunisia, Algeria, Italy, Libya, the Balkans, Iran, Iraq, India, and Yemen, with specific genetic disorders found in each regional group, or even in specific subpopulations in these regions.
|Disease||Mode of inheritance||Gene or enzyme||Carrier frequency||Populations|
|Oculocutaneous albinism||Autosomal recessive||TYR||1/30||Morocco|
|Ataxia telangiectasia||Autosomal recessive||ATM||1/80||Morocco, Tunisia|
|Creutzfeldt–Jakob disease||Autosomal dominant||PRNP||1/24,000||Libya|
|Cerebrotendinous xanthomatosis||Autosomal recessive||CYP27A1||1/70||Morocco|
|Familial Mediterranean fever||Autosomal recessive||MEFV||1/5–7||All MENA (Middle Eastern and North African countries).|
|Glycogen storage disease III||Autosomal recessive||AGL||1/35||Morocco, North Africa|
|Limb girdle muscular dystrophy||Autosomal recessive||DYSF||1/10||Libya|
|11-β-hydroxylase deficiency||Autosomal recessive||CYP11B1||1/30–1/128||Morocco|
|Disease||Mode of inheritance||Gene or enzyme||Carrier frequency||Populations|
|Beta-thalassemia||Autosomal recessive||HBB||1/6||Iran, Iraq, Kurdistan|
|Factor VII deficiency||Autosomal recessive||F7||1/40||Iran|
|Familial Mediterranean fever||Autosomal recessive, but heterozygous carriers also can show clinical manifestations.||MEFV||1/5–1/7||Iraq, Iran, Armenia, North African Jews, Ashkenazi|
|Glucose-6-phosphate dehydrogenase deficiency||X-linked||G6PD||1/4||Iraq, esp. Kurdistan, Syria and all MENA countries. Female heterozygotes can also show clinical symptoms due to lyonization (X-inactivation) especially during pregnancy.|
|Inclusion body myopathy||Autosomal recessive||GNE||1/12||Iran|
|Metachromatic leukodystrophy||Autosomal recessive||ARSA||1/50||Yemen|
|Oculopharyngeal muscular dystrophy||Autosomal, recessive or dominant||PABPN1||1/7||Bukhara|
Genetic testing in Jewish populations
One of the first genetic testing programs to identify heterozygote carriers of a genetic disorder was a program aimed at eliminating Tay–Sachs disease. This program began in 1970, and over one million people have now been screened for the mutation. Identifying carriers and counseling couples on reproductive options have had a large impact on the incidence of the disease, with a decrease from 40–50 per year worldwide to only four or five per year. Screening programs now test for several genetic disorders in Jews, although these focus on the Ashkenazi Jews, since other Jewish groups cannot be given a single set of tests for a common set of disorders. In the USA, these screening programs have been widely accepted by the Ashkenazi community, and have greatly reduced the frequency of the disorders.
Prenatal testing for several genetic diseases is offered as commercial panels for Ashkenazi couples by both CIGNA and Quest Diagnostics. The CIGNA panel is available for testing for parental/preconception screening or following chorionic villus sampling or amniocentesis and tests for Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia, Gaucher disease, mucolipidosis IV, Neimann-Pick disease type A, Tay-Sachs disease, and torsion dystonia. The Quest panel is for parental/preconception testing and tests for Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia group C, Gaucher disease, Neimann-Pick disease types A and B, and Tay-Sachs disease.
The official recommendations of the American College of Obstetricians and Gynecologists is that Ashkenazi individuals be offered screening for Tay-Sachs disease, Canavan disease, cystic fibrosis, and familial dysautonomia as part of routine obstetrical care.
In the orthodox community, an organization called Dor Yeshorim carries out anonymous genetic screening of couples before marriage to reduce the risk of children with genetic diseases being born. The program educates young people on medical genetics and screens school-aged children for any disease genes. These results are then entered into an anonymous database, identified only by a unique ID number given to the person who was tested. If two people are considering getting married, they call the organization and tell them their ID numbers. The organization then tells them if they are genetically compatible. It is not divulged if one member is a carrier, so as to protect the carrier and his or her family from stigmatization. However, this program has been criticized for exerting social pressure on people to be tested, and for screening for a broad range of recessive genes, including disorders such as Gaucher disease.
- Ethnicity and health
- Finnish heritage disease
- Genetic studies on Jews
- Jewish genealogy
- Jewish medical ethics
- Rosner G, Rosner S, Orr-Urtreger A (2009). "Genetic testing in Israel: an overview". Annual Review of Genomics and Human Genetics. 10: 175–92. doi:10.1146/annurev.genom.030308.111406. PMID 19453249.
- Bloch T (August 21, 2009). "Sephardi Jews lack screening programs for their genetic diseases". Haaretz.
- Kolata G (December 7, 1993). "Nightmare or the Dream Of a New Era in Genetics?". New York Times.
- Ostrer H (November 2001). "A genetic profile of contemporary Jewish populations". Nature Reviews. Genetics. 2 (11): 891–8. doi:10.1038/35098506. PMID 11715044.
- Levin M (1999). "Screening Jews and genes: a consideration of the ethics of genetic screening within the Jewish community: challenges and responses". Genetic Testing. 3 (2): 207–13. doi:10.1089/gte.1999.3.207. PMID 10464669.
- Abel 2001, p. 7
- Bachrach S (July 2004). "In the name of public health--Nazi racial hygiene". The New England Journal of Medicine. 351 (5): 417–20. doi:10.1056/NEJMp048136. PMID 15282346.
- Modell B, Darr A (March 2002). "Science and society: genetic counselling and customary consanguineous marriage". Nature Reviews. Genetics. 3 (3): 225–9. doi:10.1038/nrg754. PMID 11972160.
- Paul DB, Spencer HG (December 2008). Keller EF, ed. ""It's ok, we're not cousins by blood": the cousin marriage controversy in historical perspective". PLoS Biology. 6 (12): 2627–30. doi:10.1371/journal.pbio.0060320. PMC 2605922. PMID 19108607.
- Carmeli DB (September 2004). "Prevalence of Jews as subjects in genetic research: figures, explanation, and potential implications". American Journal of Medical Genetics. Part A. 130A (1): 76–83. doi:10.1002/ajmg.a.20291. PMID 15368499.
- Atzmon G, Schechter C, Greiner W, Davidson D, Rennert G, Barzilai N (February 2004). "Clinical phenotype of families with longevity". Journal of the American Geriatrics Society. 52 (2): 274–7. doi:10.1111/j.1532-5415.2004.52068.x. PMID 14728640.
- Atzmon G, Cho M, Cawthon RM, Budagov T, Katz M, Yang X, et al. (January 2010). "Evolution in health and medicine Sackler colloquium: Genetic variation in human telomerase is associated with telomere length in Ashkenazi centenarians". Proceedings of the National Academy of Sciences of the United States of America. 107 Suppl 1 (suppl_1): 1710–7. Bibcode:2010PNAS..107.1710A. doi:10.1073/pnas.0906191106. PMC 2868292. PMID 19915151.
- Iveson MH, Cukic I, Der G, Batty GD, Deary IJ (February 2018). "Intelligence and all-cause mortality in the 6-Day Sample of the Scottish Mental Survey 1947 and their siblings: testing the contribution of family background". International Journal of Epidemiology. 47 (1): 89–96. doi:10.1093/ije/dyx168. PMC 5837228. PMID 29025063.
- Cochran G, Hardy J, Harpending H (September 2006). "Natural history of Ashkenazi intelligence". Journal of Biosocial Science. 38 (5): 659–93. doi:10.1017/S0021932005027069. PMID 16867211.
- Carmi S, Hui KY, Kochav E, Liu X, Xue J, Grady F, et al. (9 September 2014). "Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins". Nature Communications. 5 (1). Bibcode:2014NatCo...5E4835C. doi:10.1038/ncomms5835. Lay summary – Haaretz.
- Behar DM, Hammer MF, Garrigan D, Villems R, Bonne-Tamir B, Richards M, Gurwitz D, Rosengarten D, Kaplan M, Della Pergola S, Quintana-Murci L, Skorecki K, et al. (May 2004). "MtDNA evidence for a genetic bottleneck in the early history of the Ashkenazi Jewish population". European Journal of Human Genetics. 12 (5): 355–64. doi:10.1038/sj.ejhg.5201156. PMID 14722586.
- Wade N (March 4, 2003). "Diseases Common in Ashkenazim May Be Random". New York Times.
- Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, Yagev-More H, Bar-Shira A, Giladi N, et al. (October 2007). "The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?". Neurology. 69 (16): 1595–602. doi:10.1212/01.wnl.0000277637.33328.d8. PMID 17938369.
- "Tay–Sachs Disease Information Page". National Institute of Neurological Disorders and Stroke. February 14, 2007. Retrieved May 25, 2008.
- Sutton VR (June 2002). "Tay-Sachs disease screening and counseling families at risk for metabolic disease". Obstetrics and Gynecology Clinics of North America. 29 (2): 287–96. doi:10.1016/S0889-8545(01)00002-X. PMID 12108829.
- Buckles J (August 20, 2001). "The Success Story of Gene Tests". Genome News Network, J. Craig Venter Institute. Retrieved April 14, 2008.
- Diaz GA, Gelb BD, Risch N, Nygaard TG, Frisch A, Cohen IJ, Miranda CS, Amaral O, Maire I, Poenaru L, Caillaud C, Weizberg M, Mistry P, Desnick RJ, et al. (June 2000). "Gaucher disease: the origins of the Ashkenazi Jewish N370S and 84GG acid beta-glucosidase mutations". American Journal of Human Genetics. 66 (6): 1821–32. doi:10.1086/302946. PMC 1378046. PMID 10777718.'
- "National Gaucher Foundation". Archived from the original on May 17, 2007. Retrieved May 30, 2007.
- "Diseases: Mucolipidosis". Mount Sinai – Center for Jewish Genetic Diseases – Department of Human Genetics. Archived from the original on 17 February 2007.
- "Ashkenazi Disorders: Mendelian – Niemann–Pick disease". The Chicago Center for Jewish Genetic Disorders.
- Boas FE (August 2000). "Linkage to Gaucher mutations in the Ashkenazi population: effect of drift on decay of linkage disequilibrium and evidence for heterozygote selection". Blood Cells, Molecules & Diseases. 26 (4): 348–59. doi:10.1006/bcmd.2000.0314. PMID 11042036.
- Harpending H, Cochran G (March 2006). "Genetic diversity and genetic burden in humans". Infection, Genetics and Evolution. 6 (2): 154–62. doi:10.1016/j.meegid.2005.04.002. PMID 16246638.
- "Ashkenazi Disorders: Mendelian – Familial dysautonomia". The Chicago Center for Jewish Genetic Disorders.
- about one in 30 Ashkenazi Jews carry the disease, compared to 1 in 3000 of the general population
- "Ashkenazi Jews and Colorectal Cancer". The Chicago Center for Jewish Genetic Disorders.
- "Ashkenazi Disorders: Mendelian – Non-Classical Adrenal Hyperplasia". Jewish Genetic Disorders Organization.
- Shalimar A, Sharaf I, Farah Wahida I, Ruszymah BH (December 2007). "Congenital insensitivity to pain with anhydrosis in a Malaysian family: a genetic analysis" (PDF). Journal of Orthopaedic Surgery. 15 (3): 357–60. doi:10.1177/230949900701500323. PMID 18162686.
Type III is familial dysautonomia or Riley–Day syndrome. It is multisystemic and affects mainly Ashkenazi Jews.
- Shugart YY, Silverberg MS, Duerr RH, Taylor KD, Wang MH, Zarfas K, et al. (March 2008). "An SNP linkage scan identifies significant Crohn's disease loci on chromosomes 13q13.3 and, in Jewish families, on 1p35.2 and 3q29". Genes and Immunity. 9 (2): 161–7. doi:10.1038/sj.gene.6364460. PMC 3858857. PMID 18246054. Lay summary – Eurek Alert.
- Gutkind L, Kennedy P (10 October 2013). An Immense New Power to Heal: The Promise of Personalized Medicine. Underland Press. pp. 36–. ISBN 978-1-937163-07-5.
- Weissmann A, Linn S, Weltfriend S, Friedman-Birnbaum R (March 2000). "Epidemiological study of classic Kaposi's sarcoma: a retrospective review of 125 cases from Northern Israel". Journal of the European Academy of Dermatology and Venereology. 14 (2): 91–5. doi:10.1046/j.1468-3083.2000.00022.x. PMID 10972092.
- "Ashkenazi Jewish Diseases". Tufts Medical Center.
- "Ashkenazi Disorders: Mendelian – Mucolipidosis IV:". The Chicago Center for Jewish Genetic Disorders.
- "Myeloproliferative Neoplasms". Cancer Network.
- "Ashkenazi Disorders: Mendelian – Nonsyndromic Hearing Loss and Deafness, DFNB1 (Connexin 26)". The Chicago Center for Jewish Genetic Disorders.
- Bonifati V (October 2006). "Parkinson's disease: the LRRK2-G2019S mutation: opening a novel era in Parkinson's disease genetics". European Journal of Human Genetics. 14 (10): 1061–2. doi:10.1038/sj.ejhg.5201695. PMID 16835587.
- Lesage S, Patin E, Condroyer C, Leutenegger AL, Lohmann E, Giladi N, et al. (May 2010). "Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans". Human Molecular Genetics. 19 (10): 1998–2004. doi:10.1093/hmg/ddq081. PMID 20197411.
- Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. (November 2004). "Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology". Neuron. 44 (4): 601–7. doi:10.1016/j.neuron.2004.11.005. PMID 15541309.
We have previously linked families with autosomal-dominant, late-onset parkinsonism to chromosome 12p11.2-q13.1 (PARK8)...
- Klein J, Sato A (September 2000). "The HLA system. Second of two parts". The New England Journal of Medicine. 343 (11): 782–6. doi:10.1056/NEJM200009143431106. PMID 10984567.
- Efrati I (26 November 2013). "Scientists Discover Gene That Predisposes Ashkenazi Jews to Schizophrenia". Haaretz Newspaper.
- Glycogen Storage Disease Type Ia Mutation Analysis (Ashkenazi Jewish)"
- Ahn JK, Lev D, Leshinsky-Silver E, Ginzberg M, Lerman-Sagie T (June 2003). "A new autosomal recessive syndrome with Zellweger-like manifestations". American Journal of Medical Genetics. Part A. 119A (3): 352–5. doi:10.1002/ajmg.a.20124. PMID 12784304.
A son and daughter of consanguineous Ashkenazi Jewish parents presented with phenotypic features that are typically seen in Zellweger syndrome...
- Marek-Yagel D, Berkun Y, Padeh S, Abu A, Reznik-Wolf H, Livneh A, Pras M, Pras E (June 2009). "Clinical disease among patients heterozygous for familial Mediterranean fever". Arthritis and Rheumatism. 60 (6): 1862–6. doi:10.1002/art.24570. PMID 19479871.
- "Women with G6PD Deficiency". g6pd-deficiency.org.
- Kaback MM (December 2000). "Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model". European Journal of Pediatrics. 159 Suppl 3 (Suppl 3): S192–5. doi:10.1007/PL00014401. PMID 11216898.
- Kronn D, Jansen V, Ostrer H (April 1998). "Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, New York, NY". Archives of Internal Medicine. 158 (7): 777–81. doi:10.1001/archinte.158.7.777. PMID 9554684.
- ACOG committee on genetics (October 2009). "ACOG Committee Opinion No. 442: Preconception and prenatal carrier screening for genetic diseases in individuals of Eastern European Jewish descent". Obstetrics and Gynecology. 114 (4): 950–3. doi:10.1097/AOG.0b013e3181bd12f4. PMID 19888064.
- Ekstein J, Katzenstein H (2001). "The Dor Yeshorim story: community-based carrier screening for Tay-Sachs disease". Advances in Genetics. Advances in Genetics. 44: 297–310. doi:10.1016/S0065-2660(01)44087-9. ISBN 978-0-12-017644-1. PMID 11596991.
- Abel EL (2001). Jewish genetic disorders: a layman's guide. Jefferson, N.C: McFarland. ISBN 0-7864-0941-X.
- Goodman RM (1979). Genetic disorders among the Jewish people. Baltimore: Johns Hopkins University Press. ISBN 0-8018-2120-7.
- Goldstein DI (2009). Jacob's Legacy: A Genetic View of Jewish History. New Haven, Conn: Yale University Press. ISBN 0-300-15128-4.
- Guha S, Rosenfeld JA, Malhotra AK, Lee AT, Gregersen PK, Kane JM, Pe'er I, Darvasi A, Lencz T (January 2012). "Implications for health and disease in the genetic signature of the Ashkenazi Jewish population". Genome Biology. 13 (1): R2. doi:10.1186/gb-2012-13-1-r2. PMC 3334583. PMID 22277159.
- Chicago Center for Jewish Genetic Disorders
- Ashkenazi Jews – The Hebrew University of Jerusalem
- Jewish Diseases Genetic Testing – The Center for Medical Genetics
- Ashkenazi Jewish Genetic Diseases – Victor Center for Jewish Genetic Diseases
- Ashkenazi Jewish Diseases – Tufts Medical Center
- Jewish Genetic Disease Consortium
- Center for Jewish Genetic Diseases – Mount Sinai Medical Center
- Mendelian disorders among Jews – Israeli National Genetic Database
- Studies Show Jews’ Genetic Similarity by The New York Times